Oxlumo

OXLUMO is a targeted RNA interference–based therapy developed to address a rare inherited metabolic condition that affects how the body processes oxalate. This condition leads to excessive oxalate production in the liver, which can result in the formation of calcium oxalate deposits in the kidneys and other organs. Over time, these deposits may cause kidney stones, nephrocalcinosis, and progressive kidney damage.
The active component in OXLUMO works by reducing the activity of a specific liver enzyme involved in oxalate formation. By lowering oxalate production at its source, it helps decrease oxalate levels in the body. This targeted approach supports better metabolic balance and helps protect kidney function over the long term.
OXLUMO is designed using advanced RNA technology that selectively silences the gene responsible for excessive oxalate synthesis. Its action is highly specific to liver cells, which enhances effectiveness while limiting impact on other biological pathways. This precision makes it a significant advancement in the management of rare genetic metabolic disorders.
Clinical studies have demonstrated that OXLUMO can significantly reduce urinary and plasma oxalate levels, which are key indicators of disease severity. Consistent reduction in these levels is associated with a lower risk of oxalate buildup and related complications.
Overall, OXLUMO represents an innovative, science-driven solution for individuals affected by this rare condition. By addressing the underlying genetic cause rather than only managing symptoms, it offers a modern therapeutic approach aimed at improving long-term outcomes, preserving organ health, and enhancing overall quality of life.